Ergun Y - Search Results

1

Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study.

Ergun Y, Yildirim Ozdemir N, Toptas S, Kurtipek A, Eren T, Yazici O, Sendur MA, Akinci B, Ucar G, Oksuzoglu B, Uncu D. Ergun Y, et al. J BUON. 2019 Jul-Aug;24(4):1719-1726. J BUON. 2019. PMID: 31646831 Free article.

2

Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.

Ergun Y. Ergun Y. Lancet. 2024 Jul 27;404(10450):337-338. doi: 10.1016/S0140-6736(24)01045-6. Lancet. 2024. PMID: 39067898 No abstract available.

3

A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer.

Bozkaya Y, Özdemir NY, Yazıcı O, Demirci NS, Kurtipek A, Erdem GU, Ergün Y, Zengin N. Bozkaya Y, et al. Among authors: ergun y. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):283-290. doi: 10.22034/APJCP.2018.19.1.283. Asian Pac J Cancer Prev. 2018. PMID: 29374414 Free PMC article.

4

Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.

Ergun Y, Ozdemir NY, Guner EK, Esin E, Sendur MA, Koksoy EB, Demirci NS, Eren T, Dede I, Sezer A, Engin H, Oksuzoglu B, Yalcin B, Utkan G, Zengin N, Urun Y. Ergun Y, et al. J BUON. 2018 Dec;23(7):116-121. J BUON. 2018. PMID: 30722120 Free article.

5

KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.

Ergun Y, Acikgoz Y, Bal O, Ucar G, Dirikoc M, Caliskan Yildirim E, Akdeniz N, Uncu D. Ergun Y, et al. Expert Rev Mol Diagn. 2019 Dec;19(12):1131-1140. doi: 10.1080/14737159.2019.1693266. Epub 2019 Nov 19. Expert Rev Mol Diagn. 2019. PMID: 31718325

6

Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?

Ergun Y, Bal O, Dogan M, Uncu D. Ergun Y, et al. J BUON. 2019 Nov-Dec;24(6):2435-2441. J BUON. 2019. PMID: 31983117 Free article.

7

Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?

Ergun Y, Bal O, Dogan M, Ucar G, Dirikoc M, Acikgoz Y, Bacaksiz F, Uncu D. Ergun Y, et al. J Res Med Sci. 2020 Feb 20;25:14. doi: 10.4103/jrms.JRMS_1056_18. eCollection 2020. J Res Med Sci. 2020. PMID: 32174986 Free PMC article.

8

The prognostic value of the prognostic nutritional index in patients with metastatic colorectal cancer.

Ucar G, Ergun Y, Acikgoz Y, Uncu D. Ucar G, et al. Among authors: ergun y. Asia Pac J Clin Oncol. 2020 Oct;16(5):e179-e184. doi: 10.1111/ajco.13328. Epub 2020 Apr 16. Asia Pac J Clin Oncol. 2020. PMID: 32301263

9

Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients.

Eren T, Karacin C, Ucar G, Ergun Y, Yazici O, İmamoglu Gİ, Ozdemir N. Eren T, et al. Among authors: ergun y. Medicine (Baltimore). 2020 May 29;99(22):e20346. doi: 10.1097/MD.0000000000020346. Medicine (Baltimore). 2020. PMID: 32481414 Free article.

10

The effect of chemotherapy on olfactory function and mucociliary clearance.

Eravcı FC, Uçar G, Özcan KM, Çolak M, Ergün Y, Açıkgöz Y, Ikincioğulları A, Uncu D, Dere HH. Eravcı FC, et al. Among authors: ergun y. Support Care Cancer. 2021 Mar;29(3):1635-1641. doi: 10.1007/s00520-020-05639-y. Epub 2020 Aug 4. Support Care Cancer. 2021. PMID: 32749656

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters